Global (United States, European Union and China) Gastrointestinal Cancer Drugs

Gastrointestinal Cancer Drugs Comprehensive Study by Application (Hospitals, Specialized Cancer Treatment Centers, Clinics, Ambulatory Surgical Centers), Drug Type (Ramucirumab, Docetaxel, Doxorubicin Hydrochloride, Fluorouracil, Others), Therapy (Immunotherapy, Chemotherapy, Targeted Therapy, Sunitinib, Trastuzumab, Imatinib, Hormone Therapy, Adjuvant Chemotherapy, Radiation Therapy, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online, Others) Players and Region - Global Market Outlook to 2027

Gastrointestinal Cancer Drugs Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 16%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Gastrointestinal Cancer Drugs
Gastrointestinal cancer refers to the group of cancers associated with the gastrointestinal tract (GI tract) and accessory organs of digestion, including the esophagus, stomach, biliary system, pancreas, small intestine, large intestine, rectum and anus. The treatment of this type of cancer depends on each patient's type and stage of cancer as well as the patient's age, overall health and preferences.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
CAGR16.0%


The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain competitive advantage through combined collaborations. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Gastrointestinal Cancer Drugs market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Bristol-Myers Squibb Company (United States), Roche Holding AG (Switzerland), Eli Lilly and Company (United States), Johnson & Johnson (United States), GlaxoSmithKline plc. (United Kingdom), Celgene Corporation (United States) and Pfizer Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Sanofi S.A. (France), Novartis AG (Switzerland) and AstraZeneca (United Kingdom).

Segmentation Overview
AMA Research has segmented the market of Global Gastrointestinal Cancer Drugs market by , Application (Hospitals, Specialized Cancer Treatment Centers, Clinics and Ambulatory Surgical Centers) and Region.



On the basis of geography, the market of Gastrointestinal Cancer Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drug Type, the sub-segment i.e. Ramucirumab will boost the Gastrointestinal Cancer Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Therapy, the sub-segment i.e. Immunotherapy will boost the Gastrointestinal Cancer Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Gastrointestinal Cancer Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Advancements in the Medical Science and Increased Research and Development Activities

Market Growth Drivers:
Increased Prevalence of Gastrointestinal Cancers and Huge Investments by the Major Players

Challenges:
Stringent Government Rules and Regulations

Restraints:
Side Effects of the Cancer Drugs

Opportunities:
Growth in the Health Care Industry Worldwide, Growing Geriatric Population Worldwide and Robust Increase in the Distribution Channels

Market Leaders and their expansionary development strategies
In March 2023, Merck & Co. and BeiGene entered a strategic collaboration to co-develop and co-commercialize tisleozumab vedotin (Tivdak), a drug for the treatment of advanced stomach cancer and gastroesophageal junction (GEJ) cancer
In February 2023,The FDA approved Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of adult patients with HER2-positive gastric or GEJ adenocarcinoma who have received prior trastuzumab therapy


Key Target Audience
Gastrointestinal Cancer Drugs Manufacturers, Raw Material Suppliers, Distributors, Emerging Companies and End-users

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Hospitals
  • Specialized Cancer Treatment Centers
  • Clinics
  • Ambulatory Surgical Centers
By Drug Type
  • Ramucirumab
  • Docetaxel
  • Doxorubicin Hydrochloride
  • Fluorouracil
  • Others

By Therapy
  • Immunotherapy
  • Chemotherapy
  • Targeted Therapy
  • Sunitinib
  • Trastuzumab
  • Imatinib
  • Hormone Therapy
  • Adjuvant Chemotherapy
  • Radiation Therapy
  • Others

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Gastrointestinal Cancers
      • 3.2.2. Huge Investments by the Major Players
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Advancements in the Medical Science
      • 3.4.2. Increased Research and Development Activities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Gastrointestinal Cancer Drugs, by Application, Drug Type, Therapy, Distribution Channel and Region (value, volume and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Gastrointestinal Cancer Drugs (Value)
      • 5.2.1. Global Gastrointestinal Cancer Drugs by: Application (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Specialized Cancer Treatment Centers
        • 5.2.1.3. Clinics
        • 5.2.1.4. Ambulatory Surgical Centers
      • 5.2.2. Global Gastrointestinal Cancer Drugs by: Drug Type (Value)
        • 5.2.2.1. Ramucirumab
        • 5.2.2.2. Docetaxel
        • 5.2.2.3. Doxorubicin Hydrochloride
        • 5.2.2.4. Fluorouracil
        • 5.2.2.5. Others
      • 5.2.3. Global Gastrointestinal Cancer Drugs by: Therapy (Value)
        • 5.2.3.1. Immunotherapy
        • 5.2.3.2. Chemotherapy
        • 5.2.3.3. Targeted Therapy
        • 5.2.3.4. Sunitinib
        • 5.2.3.5. Trastuzumab
        • 5.2.3.6. Imatinib
        • 5.2.3.7. Hormone Therapy
        • 5.2.3.8. Adjuvant Chemotherapy
        • 5.2.3.9. Radiation Therapy
        • 5.2.3.10. Others
      • 5.2.4. Global Gastrointestinal Cancer Drugs by: Distribution Channel (Value)
        • 5.2.4.1. Hospital Pharmacies
        • 5.2.4.2. Retail Pharmacies
        • 5.2.4.3. Online
        • 5.2.4.4. Others
      • 5.2.5. Global Gastrointestinal Cancer Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Gastrointestinal Cancer Drugs (Volume)
      • 5.3.1. Global Gastrointestinal Cancer Drugs by: Application (Volume)
        • 5.3.1.1. Hospitals
        • 5.3.1.2. Specialized Cancer Treatment Centers
        • 5.3.1.3. Clinics
        • 5.3.1.4. Ambulatory Surgical Centers
      • 5.3.2. Global Gastrointestinal Cancer Drugs by: Drug Type (Volume)
        • 5.3.2.1. Ramucirumab
        • 5.3.2.2. Docetaxel
        • 5.3.2.3. Doxorubicin Hydrochloride
        • 5.3.2.4. Fluorouracil
        • 5.3.2.5. Others
      • 5.3.3. Global Gastrointestinal Cancer Drugs by: Therapy (Volume)
        • 5.3.3.1. Immunotherapy
        • 5.3.3.2. Chemotherapy
        • 5.3.3.3. Targeted Therapy
        • 5.3.3.4. Sunitinib
        • 5.3.3.5. Trastuzumab
        • 5.3.3.6. Imatinib
        • 5.3.3.7. Hormone Therapy
        • 5.3.3.8. Adjuvant Chemotherapy
        • 5.3.3.9. Radiation Therapy
        • 5.3.3.10. Others
      • 5.3.4. Global Gastrointestinal Cancer Drugs by: Distribution Channel (Volume)
        • 5.3.4.1. Hospital Pharmacies
        • 5.3.4.2. Retail Pharmacies
        • 5.3.4.3. Online
        • 5.3.4.4. Others
      • 5.3.5. Global Gastrointestinal Cancer Drugs Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Gastrointestinal Cancer Drugs (Price)
  • 6. Gastrointestinal Cancer Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bristol-Myers Squibb Company (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Roche Holding AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Eli Lilly and Company (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Johnson & Johnson (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GlaxoSmithKline plc. (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Celgene Corporation (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
  • 7. Global Gastrointestinal Cancer Drugs Sale, by Application, Drug Type, Therapy, Distribution Channel and Region (value, volume and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Gastrointestinal Cancer Drugs (Value)
      • 7.2.1. Global Gastrointestinal Cancer Drugs by: Application (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Specialized Cancer Treatment Centers
        • 7.2.1.3. Clinics
        • 7.2.1.4. Ambulatory Surgical Centers
      • 7.2.2. Global Gastrointestinal Cancer Drugs by: Drug Type (Value)
        • 7.2.2.1. Ramucirumab
        • 7.2.2.2. Docetaxel
        • 7.2.2.3. Doxorubicin Hydrochloride
        • 7.2.2.4. Fluorouracil
        • 7.2.2.5. Others
      • 7.2.3. Global Gastrointestinal Cancer Drugs by: Therapy (Value)
        • 7.2.3.1. Immunotherapy
        • 7.2.3.2. Chemotherapy
        • 7.2.3.3. Targeted Therapy
        • 7.2.3.4. Sunitinib
        • 7.2.3.5. Trastuzumab
        • 7.2.3.6. Imatinib
        • 7.2.3.7. Hormone Therapy
        • 7.2.3.8. Adjuvant Chemotherapy
        • 7.2.3.9. Radiation Therapy
        • 7.2.3.10. Others
      • 7.2.4. Global Gastrointestinal Cancer Drugs by: Distribution Channel (Value)
        • 7.2.4.1. Hospital Pharmacies
        • 7.2.4.2. Retail Pharmacies
        • 7.2.4.3. Online
        • 7.2.4.4. Others
      • 7.2.5. Global Gastrointestinal Cancer Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Gastrointestinal Cancer Drugs (Volume)
      • 7.3.1. Global Gastrointestinal Cancer Drugs by: Application (Volume)
        • 7.3.1.1. Hospitals
        • 7.3.1.2. Specialized Cancer Treatment Centers
        • 7.3.1.3. Clinics
        • 7.3.1.4. Ambulatory Surgical Centers
      • 7.3.2. Global Gastrointestinal Cancer Drugs by: Drug Type (Volume)
        • 7.3.2.1. Ramucirumab
        • 7.3.2.2. Docetaxel
        • 7.3.2.3. Doxorubicin Hydrochloride
        • 7.3.2.4. Fluorouracil
        • 7.3.2.5. Others
      • 7.3.3. Global Gastrointestinal Cancer Drugs by: Therapy (Volume)
        • 7.3.3.1. Immunotherapy
        • 7.3.3.2. Chemotherapy
        • 7.3.3.3. Targeted Therapy
        • 7.3.3.4. Sunitinib
        • 7.3.3.5. Trastuzumab
        • 7.3.3.6. Imatinib
        • 7.3.3.7. Hormone Therapy
        • 7.3.3.8. Adjuvant Chemotherapy
        • 7.3.3.9. Radiation Therapy
        • 7.3.3.10. Others
      • 7.3.4. Global Gastrointestinal Cancer Drugs by: Distribution Channel (Volume)
        • 7.3.4.1. Hospital Pharmacies
        • 7.3.4.2. Retail Pharmacies
        • 7.3.4.3. Online
        • 7.3.4.4. Others
      • 7.3.5. Global Gastrointestinal Cancer Drugs Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Gastrointestinal Cancer Drugs (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Gastrointestinal Cancer Drugs: by Application(USD Million)
  • Table 2. Gastrointestinal Cancer Drugs Hospitals , by Region USD Million (2016-2021)
  • Table 3. Gastrointestinal Cancer Drugs Specialized Cancer Treatment Centers , by Region USD Million (2016-2021)
  • Table 4. Gastrointestinal Cancer Drugs Clinics , by Region USD Million (2016-2021)
  • Table 5. Gastrointestinal Cancer Drugs Ambulatory Surgical Centers , by Region USD Million (2016-2021)
  • Table 6. Gastrointestinal Cancer Drugs: by Drug Type(USD Million)
  • Table 7. Gastrointestinal Cancer Drugs Ramucirumab , by Region USD Million (2016-2021)
  • Table 8. Gastrointestinal Cancer Drugs Docetaxel , by Region USD Million (2016-2021)
  • Table 9. Gastrointestinal Cancer Drugs Doxorubicin Hydrochloride , by Region USD Million (2016-2021)
  • Table 10. Gastrointestinal Cancer Drugs Fluorouracil , by Region USD Million (2016-2021)
  • Table 11. Gastrointestinal Cancer Drugs Others , by Region USD Million (2016-2021)
  • Table 12. Gastrointestinal Cancer Drugs: by Therapy(USD Million)
  • Table 13. Gastrointestinal Cancer Drugs Immunotherapy , by Region USD Million (2016-2021)
  • Table 14. Gastrointestinal Cancer Drugs Chemotherapy , by Region USD Million (2016-2021)
  • Table 15. Gastrointestinal Cancer Drugs Targeted Therapy , by Region USD Million (2016-2021)
  • Table 16. Gastrointestinal Cancer Drugs Sunitinib , by Region USD Million (2016-2021)
  • Table 17. Gastrointestinal Cancer Drugs Trastuzumab , by Region USD Million (2016-2021)
  • Table 18. Gastrointestinal Cancer Drugs Imatinib , by Region USD Million (2016-2021)
  • Table 19. Gastrointestinal Cancer Drugs Hormone Therapy , by Region USD Million (2016-2021)
  • Table 20. Gastrointestinal Cancer Drugs Adjuvant Chemotherapy , by Region USD Million (2016-2021)
  • Table 21. Gastrointestinal Cancer Drugs Radiation Therapy , by Region USD Million (2016-2021)
  • Table 22. Gastrointestinal Cancer Drugs Others , by Region USD Million (2016-2021)
  • Table 23. Gastrointestinal Cancer Drugs: by Distribution Channel(USD Million)
  • Table 24. Gastrointestinal Cancer Drugs Hospital Pharmacies , by Region USD Million (2016-2021)
  • Table 25. Gastrointestinal Cancer Drugs Retail Pharmacies , by Region USD Million (2016-2021)
  • Table 26. Gastrointestinal Cancer Drugs Online , by Region USD Million (2016-2021)
  • Table 27. Gastrointestinal Cancer Drugs Others , by Region USD Million (2016-2021)
  • Table 28. South America Gastrointestinal Cancer Drugs, by Country USD Million (2016-2021)
  • Table 29. South America Gastrointestinal Cancer Drugs, by Application USD Million (2016-2021)
  • Table 30. South America Gastrointestinal Cancer Drugs, by Drug Type USD Million (2016-2021)
  • Table 31. South America Gastrointestinal Cancer Drugs, by Therapy USD Million (2016-2021)
  • Table 32. South America Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 33. Brazil Gastrointestinal Cancer Drugs, by Application USD Million (2016-2021)
  • Table 34. Brazil Gastrointestinal Cancer Drugs, by Drug Type USD Million (2016-2021)
  • Table 35. Brazil Gastrointestinal Cancer Drugs, by Therapy USD Million (2016-2021)
  • Table 36. Brazil Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 37. Argentina Gastrointestinal Cancer Drugs, by Application USD Million (2016-2021)
  • Table 38. Argentina Gastrointestinal Cancer Drugs, by Drug Type USD Million (2016-2021)
  • Table 39. Argentina Gastrointestinal Cancer Drugs, by Therapy USD Million (2016-2021)
  • Table 40. Argentina Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 41. Rest of South America Gastrointestinal Cancer Drugs, by Application USD Million (2016-2021)
  • Table 42. Rest of South America Gastrointestinal Cancer Drugs, by Drug Type USD Million (2016-2021)
  • Table 43. Rest of South America Gastrointestinal Cancer Drugs, by Therapy USD Million (2016-2021)
  • Table 44. Rest of South America Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 45. Asia Pacific Gastrointestinal Cancer Drugs, by Country USD Million (2016-2021)
  • Table 46. Asia Pacific Gastrointestinal Cancer Drugs, by Application USD Million (2016-2021)
  • Table 47. Asia Pacific Gastrointestinal Cancer Drugs, by Drug Type USD Million (2016-2021)
  • Table 48. Asia Pacific Gastrointestinal Cancer Drugs, by Therapy USD Million (2016-2021)
  • Table 49. Asia Pacific Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 50. China Gastrointestinal Cancer Drugs, by Application USD Million (2016-2021)
  • Table 51. China Gastrointestinal Cancer Drugs, by Drug Type USD Million (2016-2021)
  • Table 52. China Gastrointestinal Cancer Drugs, by Therapy USD Million (2016-2021)
  • Table 53. China Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 54. Japan Gastrointestinal Cancer Drugs, by Application USD Million (2016-2021)
  • Table 55. Japan Gastrointestinal Cancer Drugs, by Drug Type USD Million (2016-2021)
  • Table 56. Japan Gastrointestinal Cancer Drugs, by Therapy USD Million (2016-2021)
  • Table 57. Japan Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 58. India Gastrointestinal Cancer Drugs, by Application USD Million (2016-2021)
  • Table 59. India Gastrointestinal Cancer Drugs, by Drug Type USD Million (2016-2021)
  • Table 60. India Gastrointestinal Cancer Drugs, by Therapy USD Million (2016-2021)
  • Table 61. India Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 62. South Korea Gastrointestinal Cancer Drugs, by Application USD Million (2016-2021)
  • Table 63. South Korea Gastrointestinal Cancer Drugs, by Drug Type USD Million (2016-2021)
  • Table 64. South Korea Gastrointestinal Cancer Drugs, by Therapy USD Million (2016-2021)
  • Table 65. South Korea Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 66. Taiwan Gastrointestinal Cancer Drugs, by Application USD Million (2016-2021)
  • Table 67. Taiwan Gastrointestinal Cancer Drugs, by Drug Type USD Million (2016-2021)
  • Table 68. Taiwan Gastrointestinal Cancer Drugs, by Therapy USD Million (2016-2021)
  • Table 69. Taiwan Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 70. Australia Gastrointestinal Cancer Drugs, by Application USD Million (2016-2021)
  • Table 71. Australia Gastrointestinal Cancer Drugs, by Drug Type USD Million (2016-2021)
  • Table 72. Australia Gastrointestinal Cancer Drugs, by Therapy USD Million (2016-2021)
  • Table 73. Australia Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 74. Rest of Asia-Pacific Gastrointestinal Cancer Drugs, by Application USD Million (2016-2021)
  • Table 75. Rest of Asia-Pacific Gastrointestinal Cancer Drugs, by Drug Type USD Million (2016-2021)
  • Table 76. Rest of Asia-Pacific Gastrointestinal Cancer Drugs, by Therapy USD Million (2016-2021)
  • Table 77. Rest of Asia-Pacific Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 78. Europe Gastrointestinal Cancer Drugs, by Country USD Million (2016-2021)
  • Table 79. Europe Gastrointestinal Cancer Drugs, by Application USD Million (2016-2021)
  • Table 80. Europe Gastrointestinal Cancer Drugs, by Drug Type USD Million (2016-2021)
  • Table 81. Europe Gastrointestinal Cancer Drugs, by Therapy USD Million (2016-2021)
  • Table 82. Europe Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 83. Germany Gastrointestinal Cancer Drugs, by Application USD Million (2016-2021)
  • Table 84. Germany Gastrointestinal Cancer Drugs, by Drug Type USD Million (2016-2021)
  • Table 85. Germany Gastrointestinal Cancer Drugs, by Therapy USD Million (2016-2021)
  • Table 86. Germany Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 87. France Gastrointestinal Cancer Drugs, by Application USD Million (2016-2021)
  • Table 88. France Gastrointestinal Cancer Drugs, by Drug Type USD Million (2016-2021)
  • Table 89. France Gastrointestinal Cancer Drugs, by Therapy USD Million (2016-2021)
  • Table 90. France Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 91. Italy Gastrointestinal Cancer Drugs, by Application USD Million (2016-2021)
  • Table 92. Italy Gastrointestinal Cancer Drugs, by Drug Type USD Million (2016-2021)
  • Table 93. Italy Gastrointestinal Cancer Drugs, by Therapy USD Million (2016-2021)
  • Table 94. Italy Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 95. United Kingdom Gastrointestinal Cancer Drugs, by Application USD Million (2016-2021)
  • Table 96. United Kingdom Gastrointestinal Cancer Drugs, by Drug Type USD Million (2016-2021)
  • Table 97. United Kingdom Gastrointestinal Cancer Drugs, by Therapy USD Million (2016-2021)
  • Table 98. United Kingdom Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 99. Netherlands Gastrointestinal Cancer Drugs, by Application USD Million (2016-2021)
  • Table 100. Netherlands Gastrointestinal Cancer Drugs, by Drug Type USD Million (2016-2021)
  • Table 101. Netherlands Gastrointestinal Cancer Drugs, by Therapy USD Million (2016-2021)
  • Table 102. Netherlands Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 103. Rest of Europe Gastrointestinal Cancer Drugs, by Application USD Million (2016-2021)
  • Table 104. Rest of Europe Gastrointestinal Cancer Drugs, by Drug Type USD Million (2016-2021)
  • Table 105. Rest of Europe Gastrointestinal Cancer Drugs, by Therapy USD Million (2016-2021)
  • Table 106. Rest of Europe Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 107. MEA Gastrointestinal Cancer Drugs, by Country USD Million (2016-2021)
  • Table 108. MEA Gastrointestinal Cancer Drugs, by Application USD Million (2016-2021)
  • Table 109. MEA Gastrointestinal Cancer Drugs, by Drug Type USD Million (2016-2021)
  • Table 110. MEA Gastrointestinal Cancer Drugs, by Therapy USD Million (2016-2021)
  • Table 111. MEA Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 112. Middle East Gastrointestinal Cancer Drugs, by Application USD Million (2016-2021)
  • Table 113. Middle East Gastrointestinal Cancer Drugs, by Drug Type USD Million (2016-2021)
  • Table 114. Middle East Gastrointestinal Cancer Drugs, by Therapy USD Million (2016-2021)
  • Table 115. Middle East Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 116. Africa Gastrointestinal Cancer Drugs, by Application USD Million (2016-2021)
  • Table 117. Africa Gastrointestinal Cancer Drugs, by Drug Type USD Million (2016-2021)
  • Table 118. Africa Gastrointestinal Cancer Drugs, by Therapy USD Million (2016-2021)
  • Table 119. Africa Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 120. North America Gastrointestinal Cancer Drugs, by Country USD Million (2016-2021)
  • Table 121. North America Gastrointestinal Cancer Drugs, by Application USD Million (2016-2021)
  • Table 122. North America Gastrointestinal Cancer Drugs, by Drug Type USD Million (2016-2021)
  • Table 123. North America Gastrointestinal Cancer Drugs, by Therapy USD Million (2016-2021)
  • Table 124. North America Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 125. United States Gastrointestinal Cancer Drugs, by Application USD Million (2016-2021)
  • Table 126. United States Gastrointestinal Cancer Drugs, by Drug Type USD Million (2016-2021)
  • Table 127. United States Gastrointestinal Cancer Drugs, by Therapy USD Million (2016-2021)
  • Table 128. United States Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 129. Canada Gastrointestinal Cancer Drugs, by Application USD Million (2016-2021)
  • Table 130. Canada Gastrointestinal Cancer Drugs, by Drug Type USD Million (2016-2021)
  • Table 131. Canada Gastrointestinal Cancer Drugs, by Therapy USD Million (2016-2021)
  • Table 132. Canada Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 133. Mexico Gastrointestinal Cancer Drugs, by Application USD Million (2016-2021)
  • Table 134. Mexico Gastrointestinal Cancer Drugs, by Drug Type USD Million (2016-2021)
  • Table 135. Mexico Gastrointestinal Cancer Drugs, by Therapy USD Million (2016-2021)
  • Table 136. Mexico Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 137. Gastrointestinal Cancer Drugs Sales: by Application(K Units)
  • Table 138. Gastrointestinal Cancer Drugs Sales Hospitals , by Region K Units (2016-2021)
  • Table 139. Gastrointestinal Cancer Drugs Sales Specialized Cancer Treatment Centers , by Region K Units (2016-2021)
  • Table 140. Gastrointestinal Cancer Drugs Sales Clinics , by Region K Units (2016-2021)
  • Table 141. Gastrointestinal Cancer Drugs Sales Ambulatory Surgical Centers , by Region K Units (2016-2021)
  • Table 142. Gastrointestinal Cancer Drugs Sales: by Drug Type(K Units)
  • Table 143. Gastrointestinal Cancer Drugs Sales Ramucirumab , by Region K Units (2016-2021)
  • Table 144. Gastrointestinal Cancer Drugs Sales Docetaxel , by Region K Units (2016-2021)
  • Table 145. Gastrointestinal Cancer Drugs Sales Doxorubicin Hydrochloride , by Region K Units (2016-2021)
  • Table 146. Gastrointestinal Cancer Drugs Sales Fluorouracil , by Region K Units (2016-2021)
  • Table 147. Gastrointestinal Cancer Drugs Sales Others , by Region K Units (2016-2021)
  • Table 148. Gastrointestinal Cancer Drugs Sales: by Therapy(K Units)
  • Table 149. Gastrointestinal Cancer Drugs Sales Immunotherapy , by Region K Units (2016-2021)
  • Table 150. Gastrointestinal Cancer Drugs Sales Chemotherapy , by Region K Units (2016-2021)
  • Table 151. Gastrointestinal Cancer Drugs Sales Targeted Therapy , by Region K Units (2016-2021)
  • Table 152. Gastrointestinal Cancer Drugs Sales Sunitinib , by Region K Units (2016-2021)
  • Table 153. Gastrointestinal Cancer Drugs Sales Trastuzumab , by Region K Units (2016-2021)
  • Table 154. Gastrointestinal Cancer Drugs Sales Imatinib , by Region K Units (2016-2021)
  • Table 155. Gastrointestinal Cancer Drugs Sales Hormone Therapy , by Region K Units (2016-2021)
  • Table 156. Gastrointestinal Cancer Drugs Sales Adjuvant Chemotherapy , by Region K Units (2016-2021)
  • Table 157. Gastrointestinal Cancer Drugs Sales Radiation Therapy , by Region K Units (2016-2021)
  • Table 158. Gastrointestinal Cancer Drugs Sales Others , by Region K Units (2016-2021)
  • Table 159. Gastrointestinal Cancer Drugs Sales: by Distribution Channel(K Units)
  • Table 160. Gastrointestinal Cancer Drugs Sales Hospital Pharmacies , by Region K Units (2016-2021)
  • Table 161. Gastrointestinal Cancer Drugs Sales Retail Pharmacies , by Region K Units (2016-2021)
  • Table 162. Gastrointestinal Cancer Drugs Sales Online , by Region K Units (2016-2021)
  • Table 163. Gastrointestinal Cancer Drugs Sales Others , by Region K Units (2016-2021)
  • Table 164. South America Gastrointestinal Cancer Drugs Sales, by Country K Units (2016-2021)
  • Table 165. South America Gastrointestinal Cancer Drugs Sales, by Application K Units (2016-2021)
  • Table 166. South America Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 167. South America Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2016-2021)
  • Table 168. South America Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 169. Brazil Gastrointestinal Cancer Drugs Sales, by Application K Units (2016-2021)
  • Table 170. Brazil Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 171. Brazil Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2016-2021)
  • Table 172. Brazil Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 173. Argentina Gastrointestinal Cancer Drugs Sales, by Application K Units (2016-2021)
  • Table 174. Argentina Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 175. Argentina Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2016-2021)
  • Table 176. Argentina Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 177. Rest of South America Gastrointestinal Cancer Drugs Sales, by Application K Units (2016-2021)
  • Table 178. Rest of South America Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 179. Rest of South America Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2016-2021)
  • Table 180. Rest of South America Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 181. Asia Pacific Gastrointestinal Cancer Drugs Sales, by Country K Units (2016-2021)
  • Table 182. Asia Pacific Gastrointestinal Cancer Drugs Sales, by Application K Units (2016-2021)
  • Table 183. Asia Pacific Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 184. Asia Pacific Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2016-2021)
  • Table 185. Asia Pacific Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 186. China Gastrointestinal Cancer Drugs Sales, by Application K Units (2016-2021)
  • Table 187. China Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 188. China Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2016-2021)
  • Table 189. China Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 190. Japan Gastrointestinal Cancer Drugs Sales, by Application K Units (2016-2021)
  • Table 191. Japan Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 192. Japan Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2016-2021)
  • Table 193. Japan Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 194. India Gastrointestinal Cancer Drugs Sales, by Application K Units (2016-2021)
  • Table 195. India Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 196. India Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2016-2021)
  • Table 197. India Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 198. South Korea Gastrointestinal Cancer Drugs Sales, by Application K Units (2016-2021)
  • Table 199. South Korea Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 200. South Korea Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2016-2021)
  • Table 201. South Korea Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 202. Taiwan Gastrointestinal Cancer Drugs Sales, by Application K Units (2016-2021)
  • Table 203. Taiwan Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 204. Taiwan Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2016-2021)
  • Table 205. Taiwan Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 206. Australia Gastrointestinal Cancer Drugs Sales, by Application K Units (2016-2021)
  • Table 207. Australia Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 208. Australia Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2016-2021)
  • Table 209. Australia Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 210. Rest of Asia-Pacific Gastrointestinal Cancer Drugs Sales, by Application K Units (2016-2021)
  • Table 211. Rest of Asia-Pacific Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 212. Rest of Asia-Pacific Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2016-2021)
  • Table 213. Rest of Asia-Pacific Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 214. Europe Gastrointestinal Cancer Drugs Sales, by Country K Units (2016-2021)
  • Table 215. Europe Gastrointestinal Cancer Drugs Sales, by Application K Units (2016-2021)
  • Table 216. Europe Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 217. Europe Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2016-2021)
  • Table 218. Europe Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 219. Germany Gastrointestinal Cancer Drugs Sales, by Application K Units (2016-2021)
  • Table 220. Germany Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 221. Germany Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2016-2021)
  • Table 222. Germany Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 223. France Gastrointestinal Cancer Drugs Sales, by Application K Units (2016-2021)
  • Table 224. France Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 225. France Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2016-2021)
  • Table 226. France Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 227. Italy Gastrointestinal Cancer Drugs Sales, by Application K Units (2016-2021)
  • Table 228. Italy Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 229. Italy Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2016-2021)
  • Table 230. Italy Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 231. United Kingdom Gastrointestinal Cancer Drugs Sales, by Application K Units (2016-2021)
  • Table 232. United Kingdom Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 233. United Kingdom Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2016-2021)
  • Table 234. United Kingdom Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 235. Netherlands Gastrointestinal Cancer Drugs Sales, by Application K Units (2016-2021)
  • Table 236. Netherlands Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 237. Netherlands Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2016-2021)
  • Table 238. Netherlands Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 239. Rest of Europe Gastrointestinal Cancer Drugs Sales, by Application K Units (2016-2021)
  • Table 240. Rest of Europe Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 241. Rest of Europe Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2016-2021)
  • Table 242. Rest of Europe Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 243. MEA Gastrointestinal Cancer Drugs Sales, by Country K Units (2016-2021)
  • Table 244. MEA Gastrointestinal Cancer Drugs Sales, by Application K Units (2016-2021)
  • Table 245. MEA Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 246. MEA Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2016-2021)
  • Table 247. MEA Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 248. Middle East Gastrointestinal Cancer Drugs Sales, by Application K Units (2016-2021)
  • Table 249. Middle East Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 250. Middle East Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2016-2021)
  • Table 251. Middle East Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 252. Africa Gastrointestinal Cancer Drugs Sales, by Application K Units (2016-2021)
  • Table 253. Africa Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 254. Africa Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2016-2021)
  • Table 255. Africa Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 256. North America Gastrointestinal Cancer Drugs Sales, by Country K Units (2016-2021)
  • Table 257. North America Gastrointestinal Cancer Drugs Sales, by Application K Units (2016-2021)
  • Table 258. North America Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 259. North America Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2016-2021)
  • Table 260. North America Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 261. United States Gastrointestinal Cancer Drugs Sales, by Application K Units (2016-2021)
  • Table 262. United States Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 263. United States Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2016-2021)
  • Table 264. United States Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 265. Canada Gastrointestinal Cancer Drugs Sales, by Application K Units (2016-2021)
  • Table 266. Canada Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 267. Canada Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2016-2021)
  • Table 268. Canada Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 269. Mexico Gastrointestinal Cancer Drugs Sales, by Application K Units (2016-2021)
  • Table 270. Mexico Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2016-2021)
  • Table 271. Mexico Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2016-2021)
  • Table 272. Mexico Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 273. Company Basic Information, Sales Area and Its Competitors
  • Table 274. Company Basic Information, Sales Area and Its Competitors
  • Table 275. Company Basic Information, Sales Area and Its Competitors
  • Table 276. Company Basic Information, Sales Area and Its Competitors
  • Table 277. Company Basic Information, Sales Area and Its Competitors
  • Table 278. Company Basic Information, Sales Area and Its Competitors
  • Table 279. Company Basic Information, Sales Area and Its Competitors
  • Table 280. Gastrointestinal Cancer Drugs: by Application(USD Million)
  • Table 281. Gastrointestinal Cancer Drugs Hospitals , by Region USD Million (2022-2027)
  • Table 282. Gastrointestinal Cancer Drugs Specialized Cancer Treatment Centers , by Region USD Million (2022-2027)
  • Table 283. Gastrointestinal Cancer Drugs Clinics , by Region USD Million (2022-2027)
  • Table 284. Gastrointestinal Cancer Drugs Ambulatory Surgical Centers , by Region USD Million (2022-2027)
  • Table 285. Gastrointestinal Cancer Drugs: by Drug Type(USD Million)
  • Table 286. Gastrointestinal Cancer Drugs Ramucirumab , by Region USD Million (2022-2027)
  • Table 287. Gastrointestinal Cancer Drugs Docetaxel , by Region USD Million (2022-2027)
  • Table 288. Gastrointestinal Cancer Drugs Doxorubicin Hydrochloride , by Region USD Million (2022-2027)
  • Table 289. Gastrointestinal Cancer Drugs Fluorouracil , by Region USD Million (2022-2027)
  • Table 290. Gastrointestinal Cancer Drugs Others , by Region USD Million (2022-2027)
  • Table 291. Gastrointestinal Cancer Drugs: by Therapy(USD Million)
  • Table 292. Gastrointestinal Cancer Drugs Immunotherapy , by Region USD Million (2022-2027)
  • Table 293. Gastrointestinal Cancer Drugs Chemotherapy , by Region USD Million (2022-2027)
  • Table 294. Gastrointestinal Cancer Drugs Targeted Therapy , by Region USD Million (2022-2027)
  • Table 295. Gastrointestinal Cancer Drugs Sunitinib , by Region USD Million (2022-2027)
  • Table 296. Gastrointestinal Cancer Drugs Trastuzumab , by Region USD Million (2022-2027)
  • Table 297. Gastrointestinal Cancer Drugs Imatinib , by Region USD Million (2022-2027)
  • Table 298. Gastrointestinal Cancer Drugs Hormone Therapy , by Region USD Million (2022-2027)
  • Table 299. Gastrointestinal Cancer Drugs Adjuvant Chemotherapy , by Region USD Million (2022-2027)
  • Table 300. Gastrointestinal Cancer Drugs Radiation Therapy , by Region USD Million (2022-2027)
  • Table 301. Gastrointestinal Cancer Drugs Others , by Region USD Million (2022-2027)
  • Table 302. Gastrointestinal Cancer Drugs: by Distribution Channel(USD Million)
  • Table 303. Gastrointestinal Cancer Drugs Hospital Pharmacies , by Region USD Million (2022-2027)
  • Table 304. Gastrointestinal Cancer Drugs Retail Pharmacies , by Region USD Million (2022-2027)
  • Table 305. Gastrointestinal Cancer Drugs Online , by Region USD Million (2022-2027)
  • Table 306. Gastrointestinal Cancer Drugs Others , by Region USD Million (2022-2027)
  • Table 307. South America Gastrointestinal Cancer Drugs, by Country USD Million (2022-2027)
  • Table 308. South America Gastrointestinal Cancer Drugs, by Application USD Million (2022-2027)
  • Table 309. South America Gastrointestinal Cancer Drugs, by Drug Type USD Million (2022-2027)
  • Table 310. South America Gastrointestinal Cancer Drugs, by Therapy USD Million (2022-2027)
  • Table 311. South America Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 312. Brazil Gastrointestinal Cancer Drugs, by Application USD Million (2022-2027)
  • Table 313. Brazil Gastrointestinal Cancer Drugs, by Drug Type USD Million (2022-2027)
  • Table 314. Brazil Gastrointestinal Cancer Drugs, by Therapy USD Million (2022-2027)
  • Table 315. Brazil Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 316. Argentina Gastrointestinal Cancer Drugs, by Application USD Million (2022-2027)
  • Table 317. Argentina Gastrointestinal Cancer Drugs, by Drug Type USD Million (2022-2027)
  • Table 318. Argentina Gastrointestinal Cancer Drugs, by Therapy USD Million (2022-2027)
  • Table 319. Argentina Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 320. Rest of South America Gastrointestinal Cancer Drugs, by Application USD Million (2022-2027)
  • Table 321. Rest of South America Gastrointestinal Cancer Drugs, by Drug Type USD Million (2022-2027)
  • Table 322. Rest of South America Gastrointestinal Cancer Drugs, by Therapy USD Million (2022-2027)
  • Table 323. Rest of South America Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 324. Asia Pacific Gastrointestinal Cancer Drugs, by Country USD Million (2022-2027)
  • Table 325. Asia Pacific Gastrointestinal Cancer Drugs, by Application USD Million (2022-2027)
  • Table 326. Asia Pacific Gastrointestinal Cancer Drugs, by Drug Type USD Million (2022-2027)
  • Table 327. Asia Pacific Gastrointestinal Cancer Drugs, by Therapy USD Million (2022-2027)
  • Table 328. Asia Pacific Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 329. China Gastrointestinal Cancer Drugs, by Application USD Million (2022-2027)
  • Table 330. China Gastrointestinal Cancer Drugs, by Drug Type USD Million (2022-2027)
  • Table 331. China Gastrointestinal Cancer Drugs, by Therapy USD Million (2022-2027)
  • Table 332. China Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 333. Japan Gastrointestinal Cancer Drugs, by Application USD Million (2022-2027)
  • Table 334. Japan Gastrointestinal Cancer Drugs, by Drug Type USD Million (2022-2027)
  • Table 335. Japan Gastrointestinal Cancer Drugs, by Therapy USD Million (2022-2027)
  • Table 336. Japan Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 337. India Gastrointestinal Cancer Drugs, by Application USD Million (2022-2027)
  • Table 338. India Gastrointestinal Cancer Drugs, by Drug Type USD Million (2022-2027)
  • Table 339. India Gastrointestinal Cancer Drugs, by Therapy USD Million (2022-2027)
  • Table 340. India Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 341. South Korea Gastrointestinal Cancer Drugs, by Application USD Million (2022-2027)
  • Table 342. South Korea Gastrointestinal Cancer Drugs, by Drug Type USD Million (2022-2027)
  • Table 343. South Korea Gastrointestinal Cancer Drugs, by Therapy USD Million (2022-2027)
  • Table 344. South Korea Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 345. Taiwan Gastrointestinal Cancer Drugs, by Application USD Million (2022-2027)
  • Table 346. Taiwan Gastrointestinal Cancer Drugs, by Drug Type USD Million (2022-2027)
  • Table 347. Taiwan Gastrointestinal Cancer Drugs, by Therapy USD Million (2022-2027)
  • Table 348. Taiwan Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 349. Australia Gastrointestinal Cancer Drugs, by Application USD Million (2022-2027)
  • Table 350. Australia Gastrointestinal Cancer Drugs, by Drug Type USD Million (2022-2027)
  • Table 351. Australia Gastrointestinal Cancer Drugs, by Therapy USD Million (2022-2027)
  • Table 352. Australia Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 353. Rest of Asia-Pacific Gastrointestinal Cancer Drugs, by Application USD Million (2022-2027)
  • Table 354. Rest of Asia-Pacific Gastrointestinal Cancer Drugs, by Drug Type USD Million (2022-2027)
  • Table 355. Rest of Asia-Pacific Gastrointestinal Cancer Drugs, by Therapy USD Million (2022-2027)
  • Table 356. Rest of Asia-Pacific Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 357. Europe Gastrointestinal Cancer Drugs, by Country USD Million (2022-2027)
  • Table 358. Europe Gastrointestinal Cancer Drugs, by Application USD Million (2022-2027)
  • Table 359. Europe Gastrointestinal Cancer Drugs, by Drug Type USD Million (2022-2027)
  • Table 360. Europe Gastrointestinal Cancer Drugs, by Therapy USD Million (2022-2027)
  • Table 361. Europe Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 362. Germany Gastrointestinal Cancer Drugs, by Application USD Million (2022-2027)
  • Table 363. Germany Gastrointestinal Cancer Drugs, by Drug Type USD Million (2022-2027)
  • Table 364. Germany Gastrointestinal Cancer Drugs, by Therapy USD Million (2022-2027)
  • Table 365. Germany Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 366. France Gastrointestinal Cancer Drugs, by Application USD Million (2022-2027)
  • Table 367. France Gastrointestinal Cancer Drugs, by Drug Type USD Million (2022-2027)
  • Table 368. France Gastrointestinal Cancer Drugs, by Therapy USD Million (2022-2027)
  • Table 369. France Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 370. Italy Gastrointestinal Cancer Drugs, by Application USD Million (2022-2027)
  • Table 371. Italy Gastrointestinal Cancer Drugs, by Drug Type USD Million (2022-2027)
  • Table 372. Italy Gastrointestinal Cancer Drugs, by Therapy USD Million (2022-2027)
  • Table 373. Italy Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 374. United Kingdom Gastrointestinal Cancer Drugs, by Application USD Million (2022-2027)
  • Table 375. United Kingdom Gastrointestinal Cancer Drugs, by Drug Type USD Million (2022-2027)
  • Table 376. United Kingdom Gastrointestinal Cancer Drugs, by Therapy USD Million (2022-2027)
  • Table 377. United Kingdom Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 378. Netherlands Gastrointestinal Cancer Drugs, by Application USD Million (2022-2027)
  • Table 379. Netherlands Gastrointestinal Cancer Drugs, by Drug Type USD Million (2022-2027)
  • Table 380. Netherlands Gastrointestinal Cancer Drugs, by Therapy USD Million (2022-2027)
  • Table 381. Netherlands Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 382. Rest of Europe Gastrointestinal Cancer Drugs, by Application USD Million (2022-2027)
  • Table 383. Rest of Europe Gastrointestinal Cancer Drugs, by Drug Type USD Million (2022-2027)
  • Table 384. Rest of Europe Gastrointestinal Cancer Drugs, by Therapy USD Million (2022-2027)
  • Table 385. Rest of Europe Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 386. MEA Gastrointestinal Cancer Drugs, by Country USD Million (2022-2027)
  • Table 387. MEA Gastrointestinal Cancer Drugs, by Application USD Million (2022-2027)
  • Table 388. MEA Gastrointestinal Cancer Drugs, by Drug Type USD Million (2022-2027)
  • Table 389. MEA Gastrointestinal Cancer Drugs, by Therapy USD Million (2022-2027)
  • Table 390. MEA Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 391. Middle East Gastrointestinal Cancer Drugs, by Application USD Million (2022-2027)
  • Table 392. Middle East Gastrointestinal Cancer Drugs, by Drug Type USD Million (2022-2027)
  • Table 393. Middle East Gastrointestinal Cancer Drugs, by Therapy USD Million (2022-2027)
  • Table 394. Middle East Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 395. Africa Gastrointestinal Cancer Drugs, by Application USD Million (2022-2027)
  • Table 396. Africa Gastrointestinal Cancer Drugs, by Drug Type USD Million (2022-2027)
  • Table 397. Africa Gastrointestinal Cancer Drugs, by Therapy USD Million (2022-2027)
  • Table 398. Africa Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 399. North America Gastrointestinal Cancer Drugs, by Country USD Million (2022-2027)
  • Table 400. North America Gastrointestinal Cancer Drugs, by Application USD Million (2022-2027)
  • Table 401. North America Gastrointestinal Cancer Drugs, by Drug Type USD Million (2022-2027)
  • Table 402. North America Gastrointestinal Cancer Drugs, by Therapy USD Million (2022-2027)
  • Table 403. North America Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 404. United States Gastrointestinal Cancer Drugs, by Application USD Million (2022-2027)
  • Table 405. United States Gastrointestinal Cancer Drugs, by Drug Type USD Million (2022-2027)
  • Table 406. United States Gastrointestinal Cancer Drugs, by Therapy USD Million (2022-2027)
  • Table 407. United States Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 408. Canada Gastrointestinal Cancer Drugs, by Application USD Million (2022-2027)
  • Table 409. Canada Gastrointestinal Cancer Drugs, by Drug Type USD Million (2022-2027)
  • Table 410. Canada Gastrointestinal Cancer Drugs, by Therapy USD Million (2022-2027)
  • Table 411. Canada Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 412. Mexico Gastrointestinal Cancer Drugs, by Application USD Million (2022-2027)
  • Table 413. Mexico Gastrointestinal Cancer Drugs, by Drug Type USD Million (2022-2027)
  • Table 414. Mexico Gastrointestinal Cancer Drugs, by Therapy USD Million (2022-2027)
  • Table 415. Mexico Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 416. Gastrointestinal Cancer Drugs Sales: by Application(K Units)
  • Table 417. Gastrointestinal Cancer Drugs Sales Hospitals , by Region K Units (2022-2027)
  • Table 418. Gastrointestinal Cancer Drugs Sales Specialized Cancer Treatment Centers , by Region K Units (2022-2027)
  • Table 419. Gastrointestinal Cancer Drugs Sales Clinics , by Region K Units (2022-2027)
  • Table 420. Gastrointestinal Cancer Drugs Sales Ambulatory Surgical Centers , by Region K Units (2022-2027)
  • Table 421. Gastrointestinal Cancer Drugs Sales: by Drug Type(K Units)
  • Table 422. Gastrointestinal Cancer Drugs Sales Ramucirumab , by Region K Units (2022-2027)
  • Table 423. Gastrointestinal Cancer Drugs Sales Docetaxel , by Region K Units (2022-2027)
  • Table 424. Gastrointestinal Cancer Drugs Sales Doxorubicin Hydrochloride , by Region K Units (2022-2027)
  • Table 425. Gastrointestinal Cancer Drugs Sales Fluorouracil , by Region K Units (2022-2027)
  • Table 426. Gastrointestinal Cancer Drugs Sales Others , by Region K Units (2022-2027)
  • Table 427. Gastrointestinal Cancer Drugs Sales: by Therapy(K Units)
  • Table 428. Gastrointestinal Cancer Drugs Sales Immunotherapy , by Region K Units (2022-2027)
  • Table 429. Gastrointestinal Cancer Drugs Sales Chemotherapy , by Region K Units (2022-2027)
  • Table 430. Gastrointestinal Cancer Drugs Sales Targeted Therapy , by Region K Units (2022-2027)
  • Table 431. Gastrointestinal Cancer Drugs Sales Sunitinib , by Region K Units (2022-2027)
  • Table 432. Gastrointestinal Cancer Drugs Sales Trastuzumab , by Region K Units (2022-2027)
  • Table 433. Gastrointestinal Cancer Drugs Sales Imatinib , by Region K Units (2022-2027)
  • Table 434. Gastrointestinal Cancer Drugs Sales Hormone Therapy , by Region K Units (2022-2027)
  • Table 435. Gastrointestinal Cancer Drugs Sales Adjuvant Chemotherapy , by Region K Units (2022-2027)
  • Table 436. Gastrointestinal Cancer Drugs Sales Radiation Therapy , by Region K Units (2022-2027)
  • Table 437. Gastrointestinal Cancer Drugs Sales Others , by Region K Units (2022-2027)
  • Table 438. Gastrointestinal Cancer Drugs Sales: by Distribution Channel(K Units)
  • Table 439. Gastrointestinal Cancer Drugs Sales Hospital Pharmacies , by Region K Units (2022-2027)
  • Table 440. Gastrointestinal Cancer Drugs Sales Retail Pharmacies , by Region K Units (2022-2027)
  • Table 441. Gastrointestinal Cancer Drugs Sales Online , by Region K Units (2022-2027)
  • Table 442. Gastrointestinal Cancer Drugs Sales Others , by Region K Units (2022-2027)
  • Table 443. South America Gastrointestinal Cancer Drugs Sales, by Country K Units (2022-2027)
  • Table 444. South America Gastrointestinal Cancer Drugs Sales, by Application K Units (2022-2027)
  • Table 445. South America Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 446. South America Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2022-2027)
  • Table 447. South America Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 448. Brazil Gastrointestinal Cancer Drugs Sales, by Application K Units (2022-2027)
  • Table 449. Brazil Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 450. Brazil Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2022-2027)
  • Table 451. Brazil Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 452. Argentina Gastrointestinal Cancer Drugs Sales, by Application K Units (2022-2027)
  • Table 453. Argentina Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 454. Argentina Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2022-2027)
  • Table 455. Argentina Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 456. Rest of South America Gastrointestinal Cancer Drugs Sales, by Application K Units (2022-2027)
  • Table 457. Rest of South America Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 458. Rest of South America Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2022-2027)
  • Table 459. Rest of South America Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 460. Asia Pacific Gastrointestinal Cancer Drugs Sales, by Country K Units (2022-2027)
  • Table 461. Asia Pacific Gastrointestinal Cancer Drugs Sales, by Application K Units (2022-2027)
  • Table 462. Asia Pacific Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 463. Asia Pacific Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2022-2027)
  • Table 464. Asia Pacific Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 465. China Gastrointestinal Cancer Drugs Sales, by Application K Units (2022-2027)
  • Table 466. China Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 467. China Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2022-2027)
  • Table 468. China Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 469. Japan Gastrointestinal Cancer Drugs Sales, by Application K Units (2022-2027)
  • Table 470. Japan Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 471. Japan Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2022-2027)
  • Table 472. Japan Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 473. India Gastrointestinal Cancer Drugs Sales, by Application K Units (2022-2027)
  • Table 474. India Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 475. India Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2022-2027)
  • Table 476. India Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 477. South Korea Gastrointestinal Cancer Drugs Sales, by Application K Units (2022-2027)
  • Table 478. South Korea Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 479. South Korea Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2022-2027)
  • Table 480. South Korea Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 481. Taiwan Gastrointestinal Cancer Drugs Sales, by Application K Units (2022-2027)
  • Table 482. Taiwan Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 483. Taiwan Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2022-2027)
  • Table 484. Taiwan Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 485. Australia Gastrointestinal Cancer Drugs Sales, by Application K Units (2022-2027)
  • Table 486. Australia Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 487. Australia Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2022-2027)
  • Table 488. Australia Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 489. Rest of Asia-Pacific Gastrointestinal Cancer Drugs Sales, by Application K Units (2022-2027)
  • Table 490. Rest of Asia-Pacific Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 491. Rest of Asia-Pacific Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2022-2027)
  • Table 492. Rest of Asia-Pacific Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 493. Europe Gastrointestinal Cancer Drugs Sales, by Country K Units (2022-2027)
  • Table 494. Europe Gastrointestinal Cancer Drugs Sales, by Application K Units (2022-2027)
  • Table 495. Europe Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 496. Europe Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2022-2027)
  • Table 497. Europe Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 498. Germany Gastrointestinal Cancer Drugs Sales, by Application K Units (2022-2027)
  • Table 499. Germany Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 500. Germany Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2022-2027)
  • Table 501. Germany Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 502. France Gastrointestinal Cancer Drugs Sales, by Application K Units (2022-2027)
  • Table 503. France Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 504. France Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2022-2027)
  • Table 505. France Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 506. Italy Gastrointestinal Cancer Drugs Sales, by Application K Units (2022-2027)
  • Table 507. Italy Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 508. Italy Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2022-2027)
  • Table 509. Italy Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 510. United Kingdom Gastrointestinal Cancer Drugs Sales, by Application K Units (2022-2027)
  • Table 511. United Kingdom Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 512. United Kingdom Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2022-2027)
  • Table 513. United Kingdom Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 514. Netherlands Gastrointestinal Cancer Drugs Sales, by Application K Units (2022-2027)
  • Table 515. Netherlands Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 516. Netherlands Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2022-2027)
  • Table 517. Netherlands Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 518. Rest of Europe Gastrointestinal Cancer Drugs Sales, by Application K Units (2022-2027)
  • Table 519. Rest of Europe Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 520. Rest of Europe Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2022-2027)
  • Table 521. Rest of Europe Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 522. MEA Gastrointestinal Cancer Drugs Sales, by Country K Units (2022-2027)
  • Table 523. MEA Gastrointestinal Cancer Drugs Sales, by Application K Units (2022-2027)
  • Table 524. MEA Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 525. MEA Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2022-2027)
  • Table 526. MEA Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 527. Middle East Gastrointestinal Cancer Drugs Sales, by Application K Units (2022-2027)
  • Table 528. Middle East Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 529. Middle East Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2022-2027)
  • Table 530. Middle East Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 531. Africa Gastrointestinal Cancer Drugs Sales, by Application K Units (2022-2027)
  • Table 532. Africa Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 533. Africa Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2022-2027)
  • Table 534. Africa Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 535. North America Gastrointestinal Cancer Drugs Sales, by Country K Units (2022-2027)
  • Table 536. North America Gastrointestinal Cancer Drugs Sales, by Application K Units (2022-2027)
  • Table 537. North America Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 538. North America Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2022-2027)
  • Table 539. North America Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 540. United States Gastrointestinal Cancer Drugs Sales, by Application K Units (2022-2027)
  • Table 541. United States Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 542. United States Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2022-2027)
  • Table 543. United States Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 544. Canada Gastrointestinal Cancer Drugs Sales, by Application K Units (2022-2027)
  • Table 545. Canada Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 546. Canada Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2022-2027)
  • Table 547. Canada Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 548. Mexico Gastrointestinal Cancer Drugs Sales, by Application K Units (2022-2027)
  • Table 549. Mexico Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2022-2027)
  • Table 550. Mexico Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2022-2027)
  • Table 551. Mexico Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 552. Research Programs/Design for This Report
  • Table 553. Key Data Information from Secondary Sources
  • Table 554. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Gastrointestinal Cancer Drugs: by Application USD Million (2016-2021)
  • Figure 5. Global Gastrointestinal Cancer Drugs: by Drug Type USD Million (2016-2021)
  • Figure 6. Global Gastrointestinal Cancer Drugs: by Therapy USD Million (2016-2021)
  • Figure 7. Global Gastrointestinal Cancer Drugs: by Distribution Channel USD Million (2016-2021)
  • Figure 8. South America Gastrointestinal Cancer Drugs Share (%), by Country
  • Figure 9. Asia Pacific Gastrointestinal Cancer Drugs Share (%), by Country
  • Figure 10. Europe Gastrointestinal Cancer Drugs Share (%), by Country
  • Figure 11. MEA Gastrointestinal Cancer Drugs Share (%), by Country
  • Figure 12. North America Gastrointestinal Cancer Drugs Share (%), by Country
  • Figure 13. Global Gastrointestinal Cancer Drugs: by Application K Units (2016-2021)
  • Figure 14. Global Gastrointestinal Cancer Drugs: by Drug Type K Units (2016-2021)
  • Figure 15. Global Gastrointestinal Cancer Drugs: by Therapy K Units (2016-2021)
  • Figure 16. Global Gastrointestinal Cancer Drugs: by Distribution Channel K Units (2016-2021)
  • Figure 17. South America Gastrointestinal Cancer Drugs Share (%), by Country
  • Figure 18. Asia Pacific Gastrointestinal Cancer Drugs Share (%), by Country
  • Figure 19. Europe Gastrointestinal Cancer Drugs Share (%), by Country
  • Figure 20. MEA Gastrointestinal Cancer Drugs Share (%), by Country
  • Figure 21. North America Gastrointestinal Cancer Drugs Share (%), by Country
  • Figure 22. Global Gastrointestinal Cancer Drugs share by Players 2021 (%)
  • Figure 23. Global Gastrointestinal Cancer Drugs share by Players (Top 3) 2021(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 26. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2021
  • Figure 27. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. Roche Holding AG (Switzerland) Revenue: by Geography 2021
  • Figure 29. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 30. Eli Lilly and Company (United States) Revenue: by Geography 2021
  • Figure 31. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 32. Johnson & Johnson (United States) Revenue: by Geography 2021
  • Figure 33. GlaxoSmithKline plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. GlaxoSmithKline plc. (United Kingdom) Revenue: by Geography 2021
  • Figure 35. Celgene Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 36. Celgene Corporation (United States) Revenue: by Geography 2021
  • Figure 37. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Pfizer Inc. (United States) Revenue: by Geography 2021
  • Figure 39. Global Gastrointestinal Cancer Drugs: by Application USD Million (2022-2027)
  • Figure 40. Global Gastrointestinal Cancer Drugs: by Drug Type USD Million (2022-2027)
  • Figure 41. Global Gastrointestinal Cancer Drugs: by Therapy USD Million (2022-2027)
  • Figure 42. Global Gastrointestinal Cancer Drugs: by Distribution Channel USD Million (2022-2027)
  • Figure 43. South America Gastrointestinal Cancer Drugs Share (%), by Country
  • Figure 44. Asia Pacific Gastrointestinal Cancer Drugs Share (%), by Country
  • Figure 45. Europe Gastrointestinal Cancer Drugs Share (%), by Country
  • Figure 46. MEA Gastrointestinal Cancer Drugs Share (%), by Country
  • Figure 47. North America Gastrointestinal Cancer Drugs Share (%), by Country
  • Figure 48. Global Gastrointestinal Cancer Drugs: by Application K Units (2022-2027)
  • Figure 49. Global Gastrointestinal Cancer Drugs: by Drug Type K Units (2022-2027)
  • Figure 50. Global Gastrointestinal Cancer Drugs: by Therapy K Units (2022-2027)
  • Figure 51. Global Gastrointestinal Cancer Drugs: by Distribution Channel K Units (2022-2027)
  • Figure 52. South America Gastrointestinal Cancer Drugs Share (%), by Country
  • Figure 53. Asia Pacific Gastrointestinal Cancer Drugs Share (%), by Country
  • Figure 54. Europe Gastrointestinal Cancer Drugs Share (%), by Country
  • Figure 55. MEA Gastrointestinal Cancer Drugs Share (%), by Country
  • Figure 56. North America Gastrointestinal Cancer Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Bristol-Myers Squibb Company (United States)
  • Roche Holding AG (Switzerland)
  • Eli Lilly and Company (United States)
  • Johnson & Johnson (United States)
  • GlaxoSmithKline plc. (United Kingdom)
  • Celgene Corporation (United States)
  • Pfizer Inc. (United States)
Additional players considered in the study are as follows:
Sanofi S.A. (France) , Novartis AG (Switzerland) , AstraZeneca (United Kingdom)
Select User Access Type

Key Highlights of Report


Feb 2024 242 Pages 84 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global (United States, European Union and China) Gastrointestinal Cancer Drugs Quantitative research analysis
Global (United States, European Union and China) Gastrointestinal Cancer Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Bristol-Myers Squibb Company (United States), Roche Holding AG (Switzerland), Eli Lilly and Company (United States), Johnson & Johnson (United States), GlaxoSmithKline plc. (United Kingdom), Celgene Corporation (United States) and Pfizer Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Advancements in the Medical Science " is seen as one of major influencing trends for Gastrointestinal Cancer Drugs Market during projected period 2021-2027.
The Gastrointestinal Cancer Drugs market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global (United States, European Union and China) Gastrointestinal Cancer Drugs Report?

Have a Query? Click Here

Other Related Reports

Hormone Refractory Prostate Cancer Comprehensive Study by Treatment (Chemotherapy, Hormonal Therapy, Immunotherapy, Radiation Therapy, Surgery), End-users (Hospitals, Ambulatory Surgical Centers, Spe...
$ 3650
Metastatic Uveal Melanoma Thereapeutics Comprehensive Study by Type (Sunitinib Malate, Vincristine Sulfate Liposomal, LY-2801653, Sotrastaurin Acetate, Others), Application (Hospital, Clinic, Others)...
$ 3750
Brachytherapy Comprehensive Study by Type (High Dose Rate (HDR) Brachytherapy , Low Dose (LDR) Brachytherapy), Application (Prostate Cancer, Gynecological Cancer, Breast Cancer, Other Cancers), End U...
$ 3450
Q Fever Comprehensive Study by Type (Acute Q Fever, Chronic Q Fever), Treatment (Medicines (Doxycycline), Vaccination), End-users (Hospitals & Clinics, Diagnostic Centers, Surgical Centers), Diagnosi...
$ 3450
Multiple Myeloma Treatment Comprehensive Study by Application (Hospitals, Specialty Clinics, Cancer Treatment and Rehabilitation Centers, Research Organization, Laboratories), Route of Administration...
$ 3800
Mumps Virus Testing Comprehensive Study by Type (Cell Culture/Immunofluorescence, Semi-Quantitative Enzyme-Linked Immunosorbent Assay, Semi-Quantitative Chemiluminescent Immunoassay, Qualitative Real...
$ 3450